Mayra Gómez-Moreno
Interquartile rangeCancerInternal medicineRetrospective cohort studyRandomized controlled trialProspective cohort studyMedical recordAdverse effectHazard ratioObservational studyIntensive care unitDimethyl fumarateLeiomyosarcomaTolerabilityDiscontinuationComorbidityMalignancyMultiple sclerosisRituximabExpanded Disability Status ScaleNatalizumabPopulationSeverity of illnessPharmacotherapyRisk factorBreast cancerMedicineCohort
4Publications
1H-index
10Citations
Publications 4
Newest
#1Georgina Arrambide (Autonomous University of Barcelona)H-Index: 20
Last. Mayra Gómez-MorenoH-Index: 1
view all 40 authors...
Objective null To understand COVID-19 characteristics in people with multiple sclerosis (MS) and identify high-risk individuals due to their immunocompromised state resulting from the use of disease-modifying treatments. null Methods null Retrospective and multicenter registry in patients with MS with suspected or confirmed COVID-19 diagnosis and available disease course (mild = ambulatory; severe = hospitalization; and critical = intensive care unit/death). Cases were analyzed for associations ...
2 CitationsSource
Abstract Background Potential increase of cancer incidence is one of the main safety concerns of the disease-modifying therapies employed in Multiple Sclerosis (MS). Objective : Detailed description of patients who developed cancer among a prospective cohort of Spanish MS patients on dimethyl fumarate (DMF) treatment. Methods We describe patients who developed cancer among a cohort of 886 MS patients on DMF treatment (2681 patient-years), with a median time of exposure of 39.5 months (IQR 23-51....
Source
#2Julia SabinH-Index: 1
#3Victoria GalanH-Index: 4
Last. Yolanda AladroH-Index: 7
view all 25 authors...
BACKGROUND Dimethyl fumarate (DMF) has demonstrated efficacy in phase III studies. However, real-world data are still limited. OBJECTIVE The objective of this study was to describe the profile of patients who receive DMF and to assess the effectiveness of DMF regarding relapses, disability progression, magnetic resonance imaging activity, and NEDA (No Evidence Disease Activity)-3 status in a Spanish population in a real-world setting. METHODS We conducted a multicenter prospective study of patie...
1 CitationsSource
BACKGROUND: Dimethyl fumarate (DMF) tolerability and safety in multiple sclerosis (MS) has been analyzed in randomized clinical trials. Real-life studies are needed to assess possible harms of this therapy in a wider MS population. OBJECTIVE: To evaluate DMF tolerability, safety and persistence in MS in a real-world setting. METHODS: We conducted a multicenter prospective study of patients who started DMF, attended in 16 public hospitals of Spain. A specific database was elaborated to collect da...
11 CitationsSource